Article Text

Download PDFPDF
Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib
  1. Cristian Solano1,
  2. Shrinjaya Thapa2 and
  3. Mohammad Muhsin Chisti3
  1. 1William Beaumont School of Medicine, Oakland University, Rochester, Michigan, USA
  2. 2Internal Medicine, Beaumont Hospital, Royal Oak, Michigan, USA
  3. 3Hematology and Medical Oncology, William Beaumont School of Medicine, Oakland University, Troy, Michigan, USA
  1. Correspondence to Dr Cristian Solano; csolano{at}oakland.edu

Abstract

Xp11.2 translocation renal cell carcinoma (TRCC) is a rare and aggressive variant of renal cell carcinoma (RCC) when presenting in adults. We report a case of a man in his early 40s who was diagnosed with stage III Xp11.2 TRCC and underwent radical nephrectomy. Seven months following the surgery, an adrenal nodule and bilateral pulmonary nodules were discovered. He underwent cryoablation of the adrenal nodule and systemic treatment with daily pazopanib. He displayed stable disease for approximately 6 years. Following this period, multiple hospitalisations interrupted daily pazopanib therapy resulting in progression of disease. His regimen was then changed to ipilimumab and nivolumab, followed by current daily therapy with axitinib. The patient now shows stable disease in his 10th year after diagnosis. This case study demonstrates the efficacy of pazopanib for metastatic Xp11.2 TRCC and warrants further investigation to supplement the guidelines regarding the use of targeted therapy for TRCC.

  • renal medicine
  • pharmacology and therapeutics
  • oncology
  • urological cancer
  • malignant disease and immunosuppression

Statistics from Altmetric.com

Footnotes

  • Contributors CS and ST helped in collecting materials and drafting the article. All authors performed revision and final approval of the version to be published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.